Emily Bodnar, an analyst from H.C. Wainwright, maintained the Buy rating on Acrivon Therapeutics, Inc.. The associated price target remains the same with $19.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Emily Bodnar has given his Buy rating due to a combination of factors that underscore Acrivon’s clinical and financial positioning. The company is advancing its Phase 2b registrational-intent trial of ACR-368 in serous endometrial cancer, where earlier data showed notably higher response rates in serous patients versus non-serous, consistent with the drug’s CHK1/2 inhibitor mechanism in p53-mutated, HR-deficient tumors.
She also highlights that Arms 3 and 4, which are now enrolling, could both serve as potential accelerated approval pathways, with an interim analysis across 30–40 patients expected in 2H26 and full enrollment targeted by 4Q26. In parallel, Acrivon is preparing a large Phase 3 maintenance trial of ACR-368 plus anti-PD-1, backed by recent FDA interactions, and is supported by an estimated $105M in pro-forma cash, leading her to reiterate a Buy rating and maintain a $19 price target.
According to TipRanks, Bodnar is a 4-star analyst with an average return of 10.5% and a 37.95% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as Artiva Biotherapeutics, Inc., NovoCure, and Agios Pharma.